Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting January 21, 2025
Solu Therapeutics to Present First Preclinical Data of STX-0712 for the Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting January 21, 2025
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company January 16, 2025
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook January 14, 2025
Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe January 8, 2025
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease January 7, 2025
